DYSTANCE 51, a phase 2/3 clinical trial of investigational suvodirsen in Duchenne muscular dystrophy
Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating illnesses.
Wave has initiated DYSTANCE 51, a global phase 2/3 clinical trial evaluating the efficacy and safety of suvodirsen. This informational webinar will present an overview of the suvodirsen program, including the DYSTANCE 51 Phase 2/3 clinical trial.
- Shariq Ali, Vice President, Medical Affairs, Wave Life Sciences
- Jeffrey Smith, Director, Patient Advocacy, Wave Life Sciences
Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.